Skip to main content
    P

    Phibro Animal Health Corporation (PAHC)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $35.02
    -0.95 (-2.64%)

    Market Cap: $1.46B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Phibro Animal Health Corporation (PAHC) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Phibro Animal Health (PAHC) trades at 10.7x trailing earnings and 0.9x sales. Its P/E of 10.7x is below its 5-year median of 12.9x. Its forward P/E is 13.8x. The median P/E across 11 similar companies is 10.3x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 22.5% lower over the next year. Its free cash flow yield is 1.5%.

    MultipleValue
    P/E (trailing)10.7x
    Forward P/E13.8x
    Price to sales0.9x
    Price to book3.4x
    EV/EBITDA8.7x
    Price to FCF65.6x
    EV/FCF96.0x
    PEG1.7
    FCF yield1.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 36.7% below 16.9x, its P/S is 18.2% below 1.1x and its P/B is 17.1% below 4.1x.

    MultipleCurrent5-year median10-year median
    P/E10.7x12.9x16.9x
    P/S0.9x0.8x1.1x
    P/B3.4x3.1x4.1x
    Medians of month-end values through Oct 2026: 59 to 60 months (5-year) and 119 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 10.2x in 2023 to 21.8x in 2017.

    Year endPriceP/EP/SP/B
    2025$37.3613.3x1.0x4.6x
    2024$21.0013.0x0.8x3.4x
    2023$11.5810.2x0.5x1.7x
    2022$13.4110.8x0.6x2.0x
    2021$20.4216.0x0.9x3.5x
    2020$19.4216.7x1.0x3.7x
    2019$24.8319.9x1.2x4.6x
    2018$32.1618.5x1.5x6.3x
    2017$33.5021.8x1.7x8.0x
    2016$29.3019.8x1.5x10.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PAHC

    What is PAHC's forward P/E ratio?

    Phibro Animal Health has a forward P/E ratio of 13.8x.

    Is PAHC stock overvalued?

    GNG's valuation label for PAHC is Fairly valued. Its P/E of 10.7x compares with a median of 10.3x across 11 similar companies.

    What is PAHC's price to sales ratio?

    Phibro Animal Health has a price to sales ratio of 0.9x.

    What is Phibro Animal Health's average P/E ratio over 5 years?

    Phibro Animal Health's median P/E over the last 5 years is 12.9x, from 60 month-end values through Oct 2026.

    What is PAHC's PEG ratio?

    Phibro Animal Health has a PEG ratio of 1.7.